

How understanding of MS patient experiences, with respect to conversations about disease progression, differs among healthcare professions

Elisabeth G. Celius¹, Patrick Vermersch², David Yeandle³, and Alice Laroni^{4,5} on behalf of the MS in the 21st Century initiative, and Nektaria Alexandri⁶ ¹Oslo University Hospital and University of Oslo, Norway; ²Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent, Lille, FHU Imminent, Lille, FHU Imminent, Lille, FHU Imminent, Lille, Secting Group, Southampton, UK: ⁴University of Genoa, Italy; ⁵IRCCS Ospedale Policlinico San Martino, Genoa, Italy; ⁶Global Medical Affairs, Neurology & Immunology, Merck KGaA, Germany.



• Most neurologists (40.2%, n=35) first discuss disease progression with their patients at diagnosis, initiation of treatment (23.0%, n=20) or development of new symptoms (23.0%, n=20), and nurses reported most conversations at treatment initiation (30.6%, n=22) and diagnosis (27.8%, n=20) (Figure 1).



Century initiative is financially supported by Merck KGaA, Darmstadt, Germany. Secretariat support and editorial input was provided by Cello Health Communications (Owen Webb and Cassie Mackenzie) and was funded by Merck

Raed Alroughani, Birgit Bauer, Alexey Boyko, Maria Paz Giambastiani, Gavin Giovannoni, Jeremy Hobart, Jürg Kesselring, Dawn Langdon, Sarah Morrow, Jocelyne Nouvet-Gire, Celia Oreja-Guevara, Eva Kubala Havrdová, Paola Kruger, Maija Pontaga, Stanca Potra, Peter Rieckmann, Jane Shanahan, Heidi Thompson, Pieter van Galen, Patrick Vermersch, Mitzi Williams, and David Yeandle





GET POSTER PDF

DISCUSSION

In this survey, nurses were more likely than neurologists to be concerned about the ability of PwMS to cope with discussions about disease progression: nurses were half as likely as neurologists to raise the topic, and more frequently overestimated patient concerns and associated negative emotions with the conversation.

Similarly, the discrepancy between nurses and neurologists as to when disease progression is first discussed likely reflects these HCPs' respective roles in the patient pathway, e.g. neurologists typically deliver the diagnosis while nurses may be more involved in treatment initiation.

The third of PwMS who report they have not discussed disease progression with their HCP may be at a relatively early stage of disease; a significant number of HCPs reported waiting until development of new symptoms, treatment change, major relapse, or when the patient raises it with them.

However, despite feeling worried, overwhelmed and frightened by the prospect of disease progression, PwMS disagreed with HCPs that it was something they did not want to think about, cannot understand, or find too upsetting to discuss. Most PwMS do report feeling empowered enough to have these important conversations and do not want to wait until someone else raises the topic.

Of note, the high level of patient concern regarding increased disability represents an opportunity for both neurologists and nurses to proactively communicate the significant advances that have been made in MS care to slow disease progression and maintain quality of life.

• Nurses more commonly reported PwMS raising the subject of disease progression than neurologists. Nurses are more likely to be a regular point of contact for PwMS than a neurologist, so they may have more opportunities to get to know the patient, talk about social issues such as the impact of MS on their daily lives and recognise when patients are feeling upset or overwhelmed. PwMS may also feel more comfortable and confident to talk with their nurse about disease progression than their neurologist.

Conclusions

All responder groups felt it was important to be open about MS but recognised a lack of time in appointments as being a major barrier to discussing disease progression.

HCPs consistently underestimated the strong resilience of PwMS and their desire to discuss disease progression, however nurses were more likely than neurologists to "protect" PwMS from the perceived negativity of the conversation. This highlights the importance of HCPs collectively being more proactive about initiating conversations with PwMS.

Improved communications between all HCPs and PwMS can result in a better understanding of each other's perspectives and optimise conversations about disease progression to help PwMS deal with their practical and social concerns.

To find out more about MS in the 21st Century and to contribute to current and future research please visit our website www.msinthe21stcentury.com

Acknowledgements and disclosures

ved honoraria for advisory boards and/or speaker honoraria from Almirall, Biogen, Merck, Roche, Novartis, Genzyme and Teva, and unrestricted research grants from Novartis and Genzyme. eives honoraria and consulting fees from Biogen, Sanofi Genzyme, Baver, Novartis, Teva, Merck, Celgene and Almirall, Research support from Biogen, Sanofi Genzyme, Baver and Merck, avid Yeandle receives honoraria from Merck KGaA

Alice Laroni has received personal compensation from Novartis, Sanofi Genzyme, Biogen, Merck, Roche and Teva for public speaking and advisory boards. Nektaria Alexandri is an employee of Merck KGaA